共 64 条
[11]
Schlemmer A.(2001)Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial Cancer J 7 377-387
[12]
Gineyts E.(2003)Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial—the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group J Clin Oncol 21 3150-3157
[13]
Kavanagh K.L.(2002)A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma J Natl Cancer Inst 94 1458-1468
[14]
Guo K.(2008)Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions Cancer Treat Rev 34 629-639
[15]
Dunford J.E.(2005)Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial J Clin Oncol 23 3314-3321
[16]
Widler L.(2007)Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma Clin Lymphoma Myeloma 7 346-353
[17]
Jaeggi K.A.(2003)Bone resorption predicts for skeletal complications in metastatic bone disease Br J Cancer 89 2031-2037
[18]
Glatt M.(1998)Markers of bone resorption in patients treated with pamidronate Eur J Cancer 34 2021-2026
[19]
Yu J.(2002)Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma J Clin Oncol 20 2353-2359
[20]
Chang S.S.(2005)Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors J Natl Cancer Inst 97 59-69